{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:00:29Z","timestamp":1785391229191,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00228-024-03767-6","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T22:01:58Z","timestamp":1729720918000},"page":"129-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)"],"prefix":"10.1007","volume":"81","author":[{"given":"Tomoaki","family":"Akagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"3767_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21144919","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk M, Marciniak B, Kontek R (2020) Irinotecan\u2014still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci 21:1\u201321","journal-title":"Int J Mol Sci"},{"key":"3767_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00239-w","author":"H Fujii","year":"2022","unstructured":"Fujii H, Ueda Y, Hirose C et al (2022) Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci. https:\/\/doi.org\/10.1186\/s40780-022-00239-w","journal-title":"J Pharm Health Care Sci"},{"key":"3767_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/clpt.2008.152","volume":"85","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Takahashi T, Kunikane H et al (2009) Phase I\/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85:149\u2013154","journal-title":"Clin Pharmacol Ther"},{"key":"3767_CR4","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of \u03b2-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752\u20133757","journal-title":"Cancer Res"},{"key":"3767_CR5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","volume":"14","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Eckardt JR, Kuhn JG et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128\u20131135","journal-title":"J Clin Oncol"},{"key":"3767_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0885-3924(99)00149-9","volume":"19","author":"S Kornblau","year":"2000","unstructured":"Kornblau S, Benson Iii AB, Catalano R et al (2000) Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 19:118\u2013129","journal-title":"J Pain Symptom Manage"},{"key":"3767_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jpainsymman.2011.06.001","volume":"42","author":"C Regnard","year":"2011","unstructured":"Regnard C, Twycross R, Mihalyo M, Wilcock A (2011) Loperamide. J Pain Symptom Manage 42:319\u2013323","journal-title":"J Pain Symptom Manage"},{"key":"3767_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01687-6","author":"T Takeda","year":"2024","unstructured":"Takeda T, Sugimoto S, Matsumoto J, Iwata N, Nakamoto A, Ozaki AF, Hamano H, Ariyoshi N, Zamami Y (2024) A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. Int J Clin Pharm. https:\/\/doi.org\/10.1007\/s11096-023-01687-6","journal-title":"Int J Clin Pharm"},{"key":"3767_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euf.2022.07.003","volume":"9","author":"J Matsumoto","year":"2023","unstructured":"Matsumoto J, Iwata N, Watari S et al (2023) Adverse events of axitinib plus pembrolizumab versus lenvatinib plus pembrolizumab: a pharmacovigilance study in food and drug administration adverse event reporting system. Eur Urol Focus 9:141\u2013144","journal-title":"Eur Urol Focus"},{"key":"3767_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Niklas Nor\u00e9n G, Lindquist M (2014) VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65\u201377","journal-title":"Drug Saf"},{"key":"3767_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","volume":"14","author":"GN Nor\u00e9n","year":"2007","unstructured":"Nor\u00e9n GN, Orre R, Bate A, Edwards IR (2007) Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 14:305\u2013328","journal-title":"Data Min Knowl Discov"},{"key":"3767_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109\u2013117","journal-title":"Drug Saf"},{"key":"3767_CR13","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, Edwards IR (2008) A statistical methodology for drug\u2013drug interaction surveillance. Stat Med 27:3057\u20133070","journal-title":"Stat Med"},{"key":"3767_CR14","doi-asserted-by":"publisher","unstructured":"OpenAI, Achiam J, Adler S et al (2023) GPT-4 technical report. https:\/\/doi.org\/10.48550\/arXiv.2303.08774","DOI":"10.48550\/arXiv.2303.08774"},{"key":"3767_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. JNCI: J Natl Cancer Inst 91:1616\u20131634","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"3767_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545\u2013557","journal-title":"Lancet"},{"key":"3767_CR17","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P et al (2024) NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open 7:e2350756\u2013e2350756","journal-title":"JAMA Netw Open"},{"key":"3767_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s005200000220","volume":"9","author":"V Barbounis","year":"2001","unstructured":"Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258\u2013260","journal-title":"Support Care Cancer"},{"key":"3767_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31816f7b16","author":"A Guarino","year":"2008","unstructured":"Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition\/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. https:\/\/doi.org\/10.1097\/MPG.0b013e31816f7b16","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3767_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3892\/ol.2011.533","volume":"3","author":"K Hirose","year":"2012","unstructured":"Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T, Maeda Y (2012) Correlation between plasma concentration ratios of SN-38 glucuronide and sn-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett 3:694\u2013698","journal-title":"Oncol Lett"},{"key":"3767_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00520-018-4367-y","volume":"27","author":"H Hamano","year":"2019","unstructured":"Hamano H, Mitsui M, Zamami Y et al (2019) Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Support Care Cancer 27:849\u2013856","journal-title":"Support Care Cancer"},{"key":"3767_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","volume":"13","author":"O Matsuno","year":"2012","unstructured":"Matsuno O (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13:39","journal-title":"Respir Res"},{"key":"3767_CR23","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1124\/dmd.105.005447","volume":"33","author":"D Zhang","year":"2005","unstructured":"Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729","journal-title":"Drug Metab Dispos"},{"key":"3767_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D, Armand J-P, Chabot GG, Costa LD, Fadel E, Cote C, H\u00e9rait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. JNCI: J Natl Cancer Inst 86:446\u2013449","journal-title":"JNCI: J Natl Cancer Inst"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03767-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T07:14:10Z","timestamp":1735802050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03767-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3767"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03767-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with WHO policy and UMC guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}